Lab Location: #06-17   Email: hai_yan@imcb.a-star.edu.sg   Tel: 65869519

Dr. Hai Yan has made significant contributions to the field of oncology, with a career spanning academia, research, and entrepreneurship. Holding a Ph.D. in molecular biology from Columbia University and having completed his postdoctoral training under the esteemed Dr. Vogelstein and Dr. Kinzler at Johns Hopkins University, Dr. Yan has established a profound legacy in cancer genetics and biology.

In the academic sphere, Dr. Yan has held numerous prestigious positions at Duke University, School of Medicine, including the Henry S. Friedman Distinguished Professor of Neuro-Oncology and Co-Director of the Neuro-Oncology Program. His academic achievements extend to teaching and mentoring, where he has been recognized with The Bernard F. Fetter Teaching Scholar Award at Duke University School of Medicine. Notably, many of his mentees have progressed to become faculty at renowned U.S. medical schools or have ascended to leadership roles in the industry.

Dr. Yan's research has been a catalyst in advancing the understanding of molecular mechanisms underlying cancer, with an impressive h-index of 69 and over 37,626 citations to his name. His groundbreaking work includes the identification of IDH1 and IDH2 mutations in gliomas and elucidating genetic elements involved in maintaining telomere length in cancer. Notably, Dr. Yan co-authored the 2016 revision of the 4th edition of the WHO's Classification of Tumors of the Central Nervous System, which established critical molecular classification guidelines for tumor diagnosis and treatment. He holds multiple U.S. patents, including one for the clinical diagnosis and therapy of IDH1/2 mutations, and co-invented the BEAMing technology for liquid biopsy of cancer.

In the realm of entrepreneurship, Dr. Yan co-founded Genetron Health, specializing in cancer diagnostics, and under his leadership, the company went public on NASDAQ. His entrepreneurial spirit also finds expression in his role as a Venture Partner at Catalio Capital Management, where he continues to influence advancements in healthcare innovations.

Dr. Yan’s career has been embellished with numerous awards and recognitions, such as the 2014 AACR Team Science Award and the 2021 International Prize for Translational Neuroscience from the Gertrud Reemtsma Foundation and the Max Planck Society in Germany. As a senior member of the American Society for Clinical Investigation (ASCI), Dr. Yan continues to shape the future of oncology with his significant contributions, blending scientific discovery, educational leadership, and entrepreneurial acumen.

Lab Website: https://www.haiyanlab.com/